<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175915</url>
  </required_header>
  <id_info>
    <org_study_id>200907001-3-1</org_study_id>
    <nct_id>NCT01175915</nct_id>
  </id_info>
  <brief_title>A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Kanion Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Kanion Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness and safety of Reduning Injection for
      mild type of hand-foot-mouth disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By adopting a multi-center, prospective, randomized and controlled clinical trial, this study
      is aimed to evaluate the efficacy and safety of Reduning Injection in the treatment of mild
      type of Hand, Foot and Mouth Disease (HFMD), and to provide medical evidence of Reduning
      Injection for HFMD, especially to offer suggestions in clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time of bringing down the fever</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the length of time to bring down the fever by 0.5 degrees Celsius after the medicine is taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of body temperature going back to normal</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the time of the armpit temperature of lower than 37.0 degrees Celsius, lasting for at least 24 hours, after the medicine is taken.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of symptom disappearance</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the length of time when clinical symptoms and signs totally disappere after the medicine is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time of tetter disappearance</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the length of time when the tetter due to HFMD disappears, characterised by scab(s) or dropping; and time of oral ulcer concrescence, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose and usage of medicine</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the dose and frequency of using the medicine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>case severity rate</measure>
    <time_frame>10 days</time_frame>
    <description>Refering to the ratio of patient with mild type of HFMD to severe type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse reaction incidence</measure>
    <time_frame>10 days</time_frame>
    <description>Calculated by adverse event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Hand, Foot and Mouth Disease</condition>
  <arm_group>
    <arm_group_label>Western therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduning Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reduning Injection plus western therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Western therapy</intervention_name>
    <description>Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;
No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.
Intervention time: 3-7 days; Follow-up time: 3 days.</description>
    <arm_group_label>Western therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduning Injection</intervention_name>
    <description>Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;
Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;
Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.
Intervention time: 3-7 days; Follow-up time: 3 days.</description>
    <arm_group_label>Reduning Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reduning Injection plus western therapy</intervention_name>
    <description>General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;
Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;
Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.
Intervention time: 3-7 days; Follow-up time: 3 days.</description>
    <arm_group_label>Reduning Injection plus western therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of severe hand-foot-mouth disease patients according to
             Hand-Foot-Mouth Disease Treatment Guidelines 2010 issued by China's Ministry of
             Health; More than 1/3 patients should be diagnosed by etiological examination.

          -  Less than 48 hours of occurrence of mild symptoms, with an armpit temperature of more
             than 37.5 degrees Celsius.

          -  Less than 48 hours of occurrence of tetter or herpes.

          -  Age of 1-13 years.

          -  Patients or their guardians agree to participate in this study and signed the informed
             consent form.

        Exclusion Criteria:

          -  Complicated with other serious primary diseases in organ such as congenital heart
             disease, chronic hepatitis, nephritis and blood diseases, etc.

          -  With history of allergies on the experimental medicine, or severe allergies to other
             medicines.

          -  Using other western medicine or Chinese medicine for treating HFMD when consulted.

          -  Attending other clinical studies on HFMD after diagnosed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Kanion Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>An'Hui Provincial Children's Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biquan Chen</last_name>
      <phone>13856065978</phone>
      <email>anhuicbq4049@sina.com</email>
    </contact>
    <investigator>
      <last_name>Biquan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Quanzhou City Children's Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Zhuo</last_name>
      <phone>13905984912</phone>
      <email>zzq2191190@tom.com</email>
    </contact>
    <investigator>
      <last_name>Zhiqiang Zhuo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Hospital of Shijiazhuang City</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haojie Zheng</last_name>
      <phone>13933872363</phone>
      <email>zhj76711@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Haojie Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaifeng Municipal Children's Hospital</name>
      <address>
        <city>Kaifeng</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi Zhang</last_name>
      <phone>13069307700</phone>
      <email>kfzhangxi@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Xi Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial Children's Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangjie Li</last_name>
      <phone>15874162057</phone>
      <email>lesjie62@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Shuangjie Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Mu</last_name>
      <phone>13818869248</phone>
      <email>ypmu8888@126.com</email>
    </contact>
    <investigator>
      <last_name>Yongping Mu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wei Xiao</name_title>
    <organization>Jiangsu Kanion Pharmaceutical Co.,Ltd</organization>
  </responsible_party>
  <keyword>Mild type of hand, foot and mouth disease</keyword>
  <keyword>Reduning Injection</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Diseases</mesh_term>
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

